



Department of Health

MEDICINES CONTROL AGENCY



Market Towers  
1 Nine Elms Lane  
London SW8 5NQ

Telephone 01-720 2188  
Extension  
Facsimile 01-720 5647

Mr Edwards  
Bayer UK Ltd.  
Bayer House  
Strawberry Hill  
Newbury  
Berkshire

Product Name KOATE-HP  
Our Ref 00010/0169/A  
Your Ref

RG13 1JA

9th July 1990

Dear Mr Edwards,

THE MEDICINES (EXEMPTION FROM LICENCES) (CLINICAL TRIALS) ORDER 1981

I am writing to confirm that the Licensing Authority raises no objection to the change(s) in your letter of 5 JUN 90, relating to the above-mentioned Protocol Code.

Remarks:

In relation to this CTX application it is assumed that:

1. the albumin is of BP quality and is pasteurised in its final container, and
2. the heparin is not of bovine origin.

To be addressed at PL stage: Viral inactivation studies.

1. Evidence of reproducibility of virus inactivation should be supplied where absent. The effect of minimum and maximum concentrations of polysorbate 80 and TNBP should be reported in the presence of different concentrations of protein, at the maximum and minimum temperatures to be used

covering at least the minimum exposure time. The titre at suitable intermediate intervals should be presented. A suitable range of viruses should be used./ 2.The relationship between inactivation data and experimentally determined concentrations of the reactants should be specified./ 3.The temperature of the virus inactivation stage should be continuously monitored and recorded./ 4.The effect on using the single and two stages assays on the potency estimate should be addressed./ 5. The albumin and fibrinogen content should be controlled in the FPS. Specific activity and isoagglutinin limits sh

This trial may therefore proceed under the conditions previously agreed.

Yours sincerely

GRO-C